Response of discoid and subacute cutaneous lupus erythematosus to recombinant interferon alpha 2a

J Invest Dermatol. 1990 Dec;95(6 Suppl):142S-145S. doi: 10.1111/1523-1747.ep12875049.

Abstract

Ten patients suffering from discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) were treated with interferon alpha 2a. A marked improvement or clearing of cutaneous lupus erythematosus lesions was observed in eight of them. However, the response to interferon was of short duration and within a few weeks after interferon withdrawal all patients who were improved or cleared relapsed. This study suggests that interferon alpha 2a represents a new interesting approach in the treatment of DLE and SCLE. Ongoing trials will define the optimal treatment schedule for the maintenance of interferon-induced improvement of cutaneous lupus erythematosus.

MeSH terms

  • Dose-Response Relationship, Drug
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage
  • Interferon-alpha / therapeutic use*
  • Lupus Erythematosus, Cutaneous / drug therapy*
  • Lupus Erythematosus, Cutaneous / pathology
  • Lupus Erythematosus, Discoid / drug therapy*
  • Lupus Erythematosus, Discoid / pathology
  • Recombinant Proteins
  • Time Factors

Substances

  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins